Bone Cement & Glue segmentation by type distinguishes four chemical families that shape the product portfolio and influence cost structure. Polymethyl methacrylate (PMMA)‑based cements remain the dominant class, representing roughly 50 % of volume, due to their rapid polymerisation, high compressive strength, and extensive regulatory approval for orthopedic and dental fixation. Calcium‑phosphate cements, accounting for about 30 %, offer bio‑resorbability and osteoconductive properties, enabling gradual bone replacement and making them preferred for spinal augmentation and craniofacial reconstruction. Bioactive glass cements, a niche segment near 10 %, combine silicate glass particles with a reactive matrix to form a hydroxycarbonate apatite layer, providing superior bonding to both bone and soft tissue and supporting tissue engineering applications. Hybrid systems, which integrate polymeric and inorganic phases, occupy the remaining 10 % and are engineered for tailored setting times, enhanced toughness, and reduced exothermic reaction, addressing the demands of minimally invasive procedures. These type‑based divisions constitute the market taxonomy that guides manufacturers’ formulation strategies, supply‑chain sourcing, and competitive positioning within the Bone Cement & Glue market.
